NASDAQ Stock Exchange News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 768,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "86fa3f66-c244-4c54-b96c-4032675644ca",
"title": "Ames National Corp Reports Decline in Q1 2024 Earnings Amid Rising Interest Expenses",
"description": "Net Income: $2.3M for Q1 2024, down from $3.2M in Q1 2023.Earnings Per Share: $0.26 in Q1 2024, decreased from $0.36 in Q1 2023.Return on Average Assets: Decre",
"keywords": "GuruFocus, Article, News, GuruFocus Research, ATLO",
"snippet": "Ames National Corporation (Nasdaq: ATLO), a prominent bank holding company based in Iowa, disclosed a decrease in its net income for the first quarter of 2024, ...",
"url": "https://www.gurufocus.com/news/2413966/ames-national-corp-reports-decline-in-q1-2024-earnings-amid-rising-interest-expenses",
"image_url": "https://static.gurufocus.com/logos/0C00000AAZ.png?5",
"language": "en",
"published_at": "2024-04-19T21:51:43.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "ATLO",
"name": "Ames National Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 94.14056,
"sentiment_score": 0.507257,
"highlights": [
{
"highlight": "<em>Ames</em> <em>National</em> <em>Corporation</em> (<em>Nasdaq</em>: <em>ATLO</em>), a prominent bank holding company based in Iowa, disclosed a decrease in its net income for the first quarter of 2024, as detailed in its recent 8-K filing released on April 19, 2024.",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "Company Overview\n\n<em>Ames</em> <em>National</em> <em>Corporation</em> operates through its subsidiaries, offering a wide range of banking services including deposits, loans, and merchant credit card processing. Its operations span across central, north central, and south-central Iowa, focusing on both residential and commercial banking services.",
"sentiment": 0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "Despite these challenges, <em>Ames</em> <em>National</em> Corp managed to increase its loan portfolio, with net loans receivable rising to $1.27 billion from $1.22 billion. This growth, however, was offset by higher interest expenses, which climbed significantly due to market rate adjustments and a shift by customers to higher rate deposit products.",
"sentiment": 0.779,
"highlighted_in": "main_text"
},
{
"highlight": "Dividend and Stock Performance\n\n<em>Ames</em> <em>National</em> Corp declared a quarterly cash dividend of $0.27 per share, maintaining its commitment to returning value to shareholders. The stock closed at $20.18 as of the end of March 2024, with a dividend yield of 5.35%, highlighting its appeal to income-focused investors.",
"sentiment": 0.7351,
"highlighted_in": "main_text"
},
{
"highlight": "Conclusion\n\nThe first quarter of 2024 posed several financial challenges for <em>Ames</em> <em>National</em> Corp, primarily driven by the rising interest rate environment. While the company effectively managed its loan portfolio growth, the increased costs of funds have pressured profitability metrics.",
"sentiment": 0.8779,
"highlighted_in": "main_text"
},
{
"highlight": "This detailed earnings analysis is essential for investors considering the impact of market conditions on <em>Ames</em> <em>National</em> Corp's financial health and operational strategy.\n\nExplore the complete 8-K earnings release (here) from <em>Ames</em> <em>National</em> Corp for further details.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Ames</em> <em>National</em> Corp Reports Decline in Q1 2024 Earnings Amid Rising Interest Expenses",
"sentiment": 0.4588,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "099eeb95-8a80-48bb-b343-a8374c645791",
"title": "BCB Bancorp, Inc. Earns $5.9 Million in First Quarter 2024; Reports $0.32 EPS and Declares Quarterly Cash Dividend of $0.16 Per Share",
"description": "BAYONNE, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- BCB Bancorp, Inc. (the “Company”), (NASDAQ: BCBP), the holding company for BCB Community Bank (the...",
"keywords": "Nasdaq:BCBP, BCB Community Bank",
"snippet": "BAYONNE, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- BCB Bancorp, Inc. (the “Company”), (NASDAQ: BCBP), the holding company for BCB Community Bank (the “Bank...",
"url": "https://www.globenewswire.com/news-release/2024/04/19/2866367/34673/en/BCB-Bancorp-Inc-Earns-5-9-Million-in-First-Quarter-2024-Reports-0-32-EPS-and-Declares-Quarterly-Cash-Dividend-of-0-16-Per-Share.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/878b20dc-c4d1-4402-9daa-b9a79c117248",
"language": "en",
"published_at": "2024-04-19T20:15:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "BCBP",
"name": "BCB Bancorp, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 111.63072,
"sentiment_score": 0.27165,
"highlights": [
{
"highlight": "., April 19, 2024 (GLOBE NEWSWIRE) -- <em>BCB</em> <em>Bancorp</em>, <em>Inc</em>. (the “Company”), (<em>NASDAQ</em>: <em>BCBP</em>), the holding company for BCB Community Bank (the “Bank”), today reported net income of $5.9 million for the first quarter of 2024, compared to $6.1 million in the fourth quarter of 2023, and $8.1 million for the first quarter of 2023.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>BCB</em> <em>Bancorp</em>, <em>Inc</em>.\n\nEstablished in 2000 and headquartered in Bayonne, N.J., BCB Community Bank is the wholly-owned subsidiary of <em>BCB</em> <em>Bancorp</em>, <em>Inc</em>. (<em>NASDAQ</em>: <em>BCBP</em>).",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Forward-Looking Statements\n\nThis release, like many written and oral communications presented by <em>BCB</em> <em>Bancorp</em>, <em>Inc</em>., and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities",
"sentiment": 0.7906,
"highlighted_in": "main_text"
},
{
"highlight": "<em>BCB</em> <em>Bancorp</em>, <em>Inc</em>. Earns $5.9 Million in First Quarter 2024; Reports $0.32 EPS and Declares Quarterly Cash Dividend of $0.16 Per Share",
"sentiment": 0.296,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "4ff7987d-4194-4386-88a9-7eac7b64f2c6",
"title": "First Western Financial, Inc. (MYFW) Q1 2024 Earnings Call Transcript",
"description": "First Western Financial, Inc. (NASDAQ:NASDAQ:MYFW) Q1 2024 Earnings Conference Call April 19, 2024 12:00 PM ETCompany ParticipantsTony Rossi – Financial...",
"keywords": "",
"snippet": "First Western Financial, Inc. (NASDAQ:MYFW) Q1 2024 Earnings Conference Call April 19, 2024 12:00 PM ET\n\nCompany Participants\n\nTony Rossi – Financial Profiles...",
"url": "https://seekingalpha.com/article/4684789-first-western-financial-inc-myfw-q1-2024-earnings-call-transcript",
"image_url": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"language": "en",
"published_at": "2024-04-19T18:45:24.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "MYFW",
"name": "First Western Financial, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 142.16911,
"sentiment_score": 0.21716,
"highlights": [
{
"highlight": "<em>First</em> <em>Western</em> <em>Financial</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>NASDAQ:MYFW</em>) Q1 2024 Earnings Conference Call April 19, 2024 12:00 PM ET\n\nCompany Participants\n\nTony Rossi – Financial Profiles\n\nScott Wylie – Chairman and Chief Executive Officer\n\nJulie Courkamp – Chief Operating Officer\n\nDavid Weber – Chief Financial Officer\n\nConference Call Participants\n\nBrett Rabatin – Hovde Group\n\nBrady Gailey – KBW\n\nAdam Butler",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "– Piper Sandler\n\nOperator\n\nGood day and thank you for standing by and welcome to the <em>First</em> <em>Western</em> <em>Financial</em> First Quarter 2024 Earnings Conference Call.",
"sentiment": 0.8126,
"highlighted_in": "main_text"
},
{
"highlight": "Before we begin, I'd like to remind you that this conference call contains forward-looking statements with respect to the future performance and financial condition of <em>First</em> <em>Western</em> <em>Financial</em> that involve risks and uncertainties.",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "<em>First</em> <em>Western</em> <em>Financial</em>, <em>Inc</em>. (MYFW) Q1 2024 Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "859fcfd1-1db9-413c-a1b3-3b6dca565d98",
"title": "U.S. Federal Magistrate Judge Recommends Invalidation of Jetaire Patents in Lawsuit Against AerSale By Investing.com",
"description": "U.S. Federal Magistrate Judge Recommends Invalidation of Jetaire Patents in Lawsuit Against AerSale",
"keywords": "",
"snippet": "CORAL GABLES, Fla.--(BUSINESS WIRE)--AerSale Corporation (Nasdaq: ASLE) (AerSale) announced a favorable recommendation by a U.S. Federal Magistrate Judge in Aer...",
"url": "https://www.investing.com/news/press-releases/us-federal-magistrate-judge-recommends-invalidation-of-jetaire-patents-in-lawsuit-against-aersale-93CH-3387384",
"image_url": "https://i-invdn-com.investing.com/news/World_News_10_800x533_L_1420026292.jpg",
"language": "en",
"published_at": "2024-04-19T21:28:04.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "ASLE",
"name": "AerSale Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 80.40616,
"sentiment_score": 0.177567,
"highlights": [
{
"highlight": "--(BUSINESS WIRE)--<em>AerSale</em> <em>Corporation</em> (<em>Nasdaq</em>: <em>ASLE</em>) (<em>AerSale</em>) announced a favorable recommendation by a U.S.",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "On December 17, 2020, Jetaire Aerospace filed a lawsuit against <em>AerSale</em>, alleging that AerSafe products infringe three patents held by Jetaire Aerospace (the Jetaire Patents). <em>AerSale</em> filed various counterclaims against Jetaire and Mr.",
"sentiment": -0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AerSale</em> moved for judgment in its favor as a matter of law on its counterclaims regarding non- infringement and invalidity of Jetaire's patents. The U.S.",
"sentiment": -0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "Chief Magistrate Judge assigned to the case filed a report and recommendation on April 17, 2024, recommending that the District Court invalidate Jetaire's patents and enter judgment in favor of <em>AerSale</em> on these counterclaims. Should the District Court adopt this recommendation, Jetaire's patent claims would be rendered moot.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "About AerSafe ®\n\nAerSafe ® is a cost-saving solution that was designed by <em>AerSale</em> to meet the FAA's latest fuel quantity indication system (FQIS) and fuel tank flammability mitigation requirements (FTFR). The system uses precision cut reticulated polyurethane foam blocks placed in an aircraft's fuel tank.",
"sentiment": -0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>AerSale</em> ®\n\n<em>AerSale</em> serves airlines operating large jets manufactured by Boeing, Airbus and McDonnell Douglas and is dedicated to providing integrated aftermarket services and products designed to help aircraft owners and operators realize significant savings in the operation, maintenance and monetization of their aircraft, engines, and components",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "Source: <em>AerSale</em> <em>Corporation</em>\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20240419121264/en/\n\nMedia:\n\nFor more information about <em>AerSale</em>, please visit our website www.AerSale.com.",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "Follow us on: LinkedIn | Twitter | Facebook (NASDAQ: ) | Instagram\n\n<em>AerSale</em>: Jackie Carlon\n\nTelephone: (305) 764-3200\n\nEmail: [email protected]\n\nInvestor:\n\n<em>AerSale</em>: [email protected]\n\nSource: <em>AerSale</em> <em>Corporation</em>",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Federal Magistrate Judge Recommends Invalidation of Jetaire Patents in Lawsuit Against <em>AerSale</em> By Investing.com",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "ASLEW",
"name": "AerSale Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 66.16838,
"sentiment_score": 0.177567,
"highlights": [
{
"highlight": "--(BUSINESS WIRE)--<em>AerSale</em> <em>Corporation</em> (Nasdaq: ASLE) (<em>AerSale</em>) announced a favorable recommendation by a U.S.",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "On December 17, 2020, Jetaire Aerospace filed a lawsuit against <em>AerSale</em>, alleging that AerSafe products infringe three patents held by Jetaire Aerospace (the Jetaire Patents). <em>AerSale</em> filed various counterclaims against Jetaire and Mr.",
"sentiment": -0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AerSale</em> moved for judgment in its favor as a matter of law on its counterclaims regarding non- infringement and invalidity of Jetaire's patents. The U.S.",
"sentiment": -0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "Chief Magistrate Judge assigned to the case filed a report and recommendation on April 17, 2024, recommending that the District Court invalidate Jetaire's patents and enter judgment in favor of <em>AerSale</em> on these counterclaims. Should the District Court adopt this recommendation, Jetaire's patent claims would be rendered moot.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "About AerSafe ®\n\nAerSafe ® is a cost-saving solution that was designed by <em>AerSale</em> to meet the FAA's latest fuel quantity indication system (FQIS) and fuel tank flammability mitigation requirements (FTFR). The system uses precision cut reticulated polyurethane foam blocks placed in an aircraft's fuel tank.",
"sentiment": -0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>AerSale</em> ®\n\n<em>AerSale</em> serves airlines operating large jets manufactured by Boeing, Airbus and McDonnell Douglas and is dedicated to providing integrated aftermarket services and products designed to help aircraft owners and operators realize significant savings in the operation, maintenance and monetization of their aircraft, engines, and components",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "Source: <em>AerSale</em> <em>Corporation</em>\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20240419121264/en/\n\nMedia:\n\nFor more information about <em>AerSale</em>, please visit our website www.AerSale.com.",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "Follow us on: LinkedIn | Twitter | Facebook (NASDAQ: ) | Instagram\n\n<em>AerSale</em>: Jackie Carlon\n\nTelephone: (305) 764-3200\n\nEmail: [email protected]\n\nInvestor:\n\n<em>AerSale</em>: [email protected]\n\nSource: <em>AerSale</em> <em>Corporation</em>",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Federal Magistrate Judge Recommends Invalidation of Jetaire Patents in Lawsuit Against <em>AerSale</em> By Investing.com",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "27ad8033-f011-4558-9f25-623e30eaf38e",
"title": "AerSale : U.S. Federal Magistrate Judge Recommends Invalidation of Jetaire Patents in Lawsuit Against AerSale",
"description": "Coral Gables, Florida - April 19, 2024-- AerSale Corporation announced a favorable recommendation by a U.S. Federal Magistrate Judge in AerSale's lawsuit with Jetaire Aerospace, LLC, Jetaire...",
"keywords": "Markets",
"snippet": "Coral Gables, Florida - April 19, 2024-- AerSale Corporation (Nasdaq: ASLE) (\"AerSale\") announced a favorable recommendation by a U.S. Federal Magistrate Judge ...",
"url": "https://www.marketscreener.com/quote/stock/AERSALE-CORPORATION-55345357/news/AerSale-U-S-Federal-Magistrate-Judge-Recommends-Invalidation-of-Jetaire-Patents-in-Lawsuit-Agains-46481981/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
"language": "en",
"published_at": "2024-04-19T19:33:10.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "ASLE",
"name": "AerSale Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 84.83751,
"sentiment_score": 0.2621,
"highlights": [
{
"highlight": "Coral Gables, Florida - April 19, 2024-- <em>AerSale</em> <em>Corporation</em> (<em>Nasdaq</em>: <em>ASLE</em>) (\"<em>AerSale</em>\") announced a favorable recommendation by a U.S.",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "On December 17, 2020, Jetaire Aerospace filed a lawsuit against <em>AerSale</em>, alleging that AerSafe products infringe three patents held by Jetaire Aerospace (the \"Jetaire Patents\"). <em>AerSale</em> filed various counterclaims against Jetaire and Mr.",
"sentiment": -0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AerSale</em> moved for judgment in its favor as a matter of law on its counterclaims regarding non-infringement and invalidity of Jetaire's patents. The U.S.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "Chief Magistrate Judge assigned to the case filed a report and recommendation on April 17, 2024, recommending that the District Court invalidate Jetaire's patents and enter judgment in favor of <em>AerSale</em> on these counterclaims. Should the District Court adopt this recommendation, Jetaire's patent claims would be rendered moot.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "About AerSafe®\n\nAerSafe® is a cost-saving solution that was designed by <em>AerSale</em> to meet the FAA's latest fuel quantity indication system (FQIS) and fuel tank flammability mitigation requirements (FTFR). The system uses precision cut reticulated polyurethane foam blocks placed in an aircraft's fuel tank.",
"sentiment": -0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "Related Articles: Click Here to View\n\nAbout <em>AerSale</em>®\n\n<em>AerSale</em> serves airlines operating large jets manufactured by Boeing, Airbus and McDonnell Douglas and is dedicated to providing integrated aftermarket services and products designed to help aircraft owners and operators realize significant savings in the operation, maintenance and monetization of",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "AerSafe®, AerTrak®, and now AerAware™).\n\n_____________________________________________________________________________________________\n\nMedia Contacts:\n\nFor more information about <em>AerSale</em>, please visit our website: www.AerSale.com.",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AerSale</em> : U.S. Federal Magistrate Judge Recommends Invalidation of Jetaire Patents in Lawsuit Against <em>AerSale</em>",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "ASLEW",
"name": "AerSale Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 70.61598,
"sentiment_score": 0.2621,
"highlights": [
{
"highlight": "Coral Gables, Florida - April 19, 2024-- <em>AerSale</em> <em>Corporation</em> (Nasdaq: ASLE) (\"<em>AerSale</em>\") announced a favorable recommendation by a U.S.",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "On December 17, 2020, Jetaire Aerospace filed a lawsuit against <em>AerSale</em>, alleging that AerSafe products infringe three patents held by Jetaire Aerospace (the \"Jetaire Patents\"). <em>AerSale</em> filed various counterclaims against Jetaire and Mr.",
"sentiment": -0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AerSale</em> moved for judgment in its favor as a matter of law on its counterclaims regarding non-infringement and invalidity of Jetaire's patents. The U.S.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "Chief Magistrate Judge assigned to the case filed a report and recommendation on April 17, 2024, recommending that the District Court invalidate Jetaire's patents and enter judgment in favor of <em>AerSale</em> on these counterclaims. Should the District Court adopt this recommendation, Jetaire's patent claims would be rendered moot.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "About AerSafe®\n\nAerSafe® is a cost-saving solution that was designed by <em>AerSale</em> to meet the FAA's latest fuel quantity indication system (FQIS) and fuel tank flammability mitigation requirements (FTFR). The system uses precision cut reticulated polyurethane foam blocks placed in an aircraft's fuel tank.",
"sentiment": -0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "Related Articles: Click Here to View\n\nAbout <em>AerSale</em>®\n\n<em>AerSale</em> serves airlines operating large jets manufactured by Boeing, Airbus and McDonnell Douglas and is dedicated to providing integrated aftermarket services and products designed to help aircraft owners and operators realize significant savings in the operation, maintenance and monetization of",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "AerSafe®, AerTrak®, and now AerAware™).\n\n_____________________________________________________________________________________________\n\nMedia Contacts:\n\nFor more information about <em>AerSale</em>, please visit our website: www.AerSale.com.",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AerSale</em> : U.S. Federal Magistrate Judge Recommends Invalidation of Jetaire Patents in Lawsuit Against <em>AerSale</em>",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "dc96851b-8792-4a10-a424-c7210a3c77c5",
"title": "Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) By Investing.com",
"description": "Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)",
"keywords": "",
"snippet": "SAN CARLOS, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: NASDAQ: ) (Iovance or the Company), a biotechnology company focuse...",
"url": "https://www.investing.com/news/press-releases/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-93CH-3387385",
"image_url": "https://i-invdn-com.investing.com/news/news_six_pile_69x52._800x533_L_1419494215.jpg",
"language": "en",
"published_at": "2024-04-19T21:28:04.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "IOVA",
"name": "Iovance Biotherapeutics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 121.324295,
"sentiment_score": 0.039833,
"highlights": [
{
"highlight": "., April 19, 2024 (GLOBE NEWSWIRE) -- <em>Iovance</em> <em>Biotherapeutics</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Iovance</em> <em>Biotherapeutics</em>, <em>Inc</em>.\n\n<em>Iovance</em> <em>Biotherapeutics</em>, <em>Inc</em>. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.",
"sentiment": -0.7906,
"highlighted_in": "main_text"
},
{
"highlight": "Amtagvi™ and its accompanying design marks, Proleukin ®, Iovance ®, and IovanceCares™ are trademarks and registered trademarks of <em>Iovance</em> <em>Biotherapeutics</em>, <em>Inc</em>. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "Forward-Looking Statements\n\nCertain matters discussed in this press release are forward-looking statements of <em>Iovance</em> <em>Biotherapeutics</em>, <em>Inc</em>. (hereinafter referred to as the Company, we, us, or our) within the meaning of the Private Securities Litigation Reform Act of 1995 (the PSLRA).",
"sentiment": 0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "CONTACTS\n\n<em>Iovance</em> <em>Biotherapeutics</em>, <em>Inc</em>:\n\nSara Pellegrino, IRC\n\nSenior Vice President, Investor Relations & Corporate Communications\n\n650-260-7120 ext. 264\n\[email protected]\n\nJen Saunders\n\nDirector, Investor Relations & Public Relations\n\n267-485-3119\n\[email protected]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Iovance</em> <em>Biotherapeutics</em> Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) By Investing.com",
"sentiment": 0.2263,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "c673d170-05f7-4fe3-9bfd-2d775a4d510f",
"title": "Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)",
"description": "SAN CARLOS, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance” or the “Company”), a biotechnology company...",
"keywords": "Nasdaq:IOVA, Iovance Biotherapeutics Inc",
"snippet": "SAN CARLOS, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance” or the “Company”), a biotechnology compan...",
"url": "https://www.globenewswire.com/news-release/2024/04/19/2866395/0/en/Iovance-Biotherapeutics-Reports-Inducement-Grants-under-NASDAQ-Listing-Rule-5635-c-4.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/d0986bd6-4603-4e31-8ed1-f23b3e123605",
"language": "en",
"published_at": "2024-04-19T21:15:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "IOVA",
"name": "Iovance Biotherapeutics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 136.24223,
"sentiment_score": 0.076429,
"highlights": [
{
"highlight": "., April 19, 2024 (GLOBE NEWSWIRE) -- <em>Iovance</em> <em>Biotherapeutics</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>NASDAQ</em>: <em>IOVA</em>) (“Iovance” or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on April 18, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Iovance</em> <em>Biotherapeutics</em>, <em>Inc</em>.\n\n<em>Iovance</em> <em>Biotherapeutics</em>, <em>Inc</em>. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.",
"sentiment": -0.7906,
"highlighted_in": "main_text"
},
{
"highlight": "Amtagvi™ and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of <em>Iovance</em> <em>Biotherapeutics</em>, <em>Inc</em>. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "Forward-Looking Statements\n\nCertain matters discussed in this press release are “forward-looking statements” of <em>Iovance</em> <em>Biotherapeutics</em>, <em>Inc</em>. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”).",
"sentiment": 0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "CONTACTS\n\n<em>Iovance</em> <em>Biotherapeutics</em>, <em>Inc</em>:\n\nSara Pellegrino, IRC\n\nSenior Vice President, Investor Relations & Corporate Communications\n\n650-260-7120 ext. 264\n\[email protected]\n\nJen Saunders\n\nDirector, Investor Relations & Public Relations\n\n267-485-3119\n\[email protected]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Iovance</em> <em>Biotherapeutics</em> Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)",
"sentiment": 0.2263,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "2aa3d7d9-96b9-4a4c-9b6f-8b96360ea749",
"title": "Toronto Stock Exchange, Alithya Group Inc., The View From The C-Suite By Investing.com",
"description": "Toronto Stock Exchange, Alithya Group Inc., The View From The C-Suite",
"keywords": "",
"snippet": "Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amou...",
"url": "https://www.investing.com/news/press-releases/toronto-stock-exchange-alithya-group-inc-the-view-from-the-csuite-93CH-3387381",
"image_url": "https://i-invdn-com.investing.com/news/news_pile_69x52._800x533_L_1419494209.jpg",
"language": "en",
"published_at": "2024-04-19T21:24:04.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "ALYA",
"name": "Alithya Group Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 102.89633,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Toronto Stock Exchange, <em>Alithya</em> <em>Group</em> <em>Inc</em>., The View From The C-Suite By Investing.com",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "57fff316-b355-4c4e-9819-1282faadc18e",
"title": "Zai Lab files automatic ordinary shares offering (NASDAQ:ZLAB)",
"description": "Zai Lab files a prospectus for a mixed shelf offering, indicating its intention to sell securities, as per SEC filing.",
"keywords": "",
"snippet": "To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.\n\nIf you have an ad-blocker enabled you may be blocked from ...",
"url": "https://seekingalpha.com/news/4091678-zai-lab-files-automatic-ordinary-shares-offering",
"image_url": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"language": "en",
"published_at": "2024-04-19T21:20:12.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "ZLAB",
"name": "Zai Lab Limited",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 115.78643,
"sentiment_score": 0.296,
"highlights": [
{
"highlight": "<em>Zai</em> <em>Lab</em> files automatic ordinary shares offering (<em>NASDAQ:ZLAB</em>)",
"sentiment": 0.296,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "912eed0a-e2b8-403a-91f5-a2f8e3e2ee3e",
"title": "ASLAN Pharmaceuticals announces receipt of Nasdaq notice (NASDAQ:ASLN)",
"description": "ASLAN Pharmaceuticals receives notice from Nasdaq for failing to meet listing requirements, given 45 days to submit a plan for compliance.",
"keywords": "",
"snippet": "To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.\n\nIf you have an ad-blocker enabled you may be blocked from ...",
"url": "https://seekingalpha.com/news/4091677-aslan-pharmaceuticals-announces-receipt-of-nasdaq-notice",
"image_url": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"language": "en",
"published_at": "2024-04-19T21:19:32.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "ASLN",
"name": "ASLAN Pharmaceuticals Limited",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 147.10329,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>ASLAN</em> <em>Pharmaceuticals</em> announces receipt of Nasdaq notice (<em>NASDAQ:ASLN</em>)",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "6447e8b4-d553-4b02-b6f4-68c46896d852",
"title": "ENDRA Life Sciences files to sell common stock, warrants (NASDAQ:NDRA)",
"description": "ENDRA Life Sciences (NDRA) filed a prospectus related to a recent filing, expanding their presence in the financial market.",
"keywords": "",
"snippet": "To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.\n\nIf you have an ad-blocker enabled you may be blocked from ...",
"url": "https://seekingalpha.com/news/4091676-endra-life-sciences-files-to-sell-common-stock-warrants",
"image_url": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"language": "en",
"published_at": "2024-04-19T21:18:30.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "NDRA",
"name": "ENDRA Life Sciences Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 140.80191,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>ENDRA</em> <em>Life</em> <em>Sciences</em> files to sell common stock, warrants (<em>NASDAQ:NDRA</em>)",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "82fb33f6-1e1c-465d-b319-3508989f8c25",
"title": "Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Iovance Biotherapeutics (NASDAQ:IOVA)",
"description": "SAN CARLOS, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) (",
"keywords": "",
"snippet": "Loading... Loading...\n\nSAN CARLOS, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. IOVA (\"Iovance\" or the \"Company\"), a biotechnology c...",
"url": "https://www.benzinga.com/pressreleases/24/04/g38343792/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4",
"image_url": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
"language": "en",
"published_at": "2024-04-19T21:15:00.000000Z",
"source": "benzinga.com",
"relevance_score": null,
"entities": [
{
"symbol": "IOVA",
"name": "Iovance Biotherapeutics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 179.9802,
"sentiment_score": 0.039833,
"highlights": [
{
"highlight": "., April 19, 2024 (GLOBE NEWSWIRE) -- <em>Iovance</em> <em>Biotherapeutics</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Iovance</em> <em>Biotherapeutics</em>, <em>Inc</em>.\n\n<em>Iovance</em> <em>Biotherapeutics</em>, <em>Inc</em>. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.",
"sentiment": -0.7906,
"highlighted_in": "main_text"
},
{
"highlight": "Amtagvi™ and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of <em>Iovance</em> <em>Biotherapeutics</em>, <em>Inc</em>. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "Forward-Looking Statements\n\nCertain matters discussed in this press release are \"forward-looking statements\" of <em>Iovance</em> <em>Biotherapeutics</em>, <em>Inc</em>. (hereinafter referred to as the \"Company,\" \"we,\" \"us,\" or \"our\") within the meaning of the Private Securities Litigation Reform Act of 1995 (the \"PSLRA\").",
"sentiment": 0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Iovance</em> <em>Biotherapeutics</em>, <em>Inc</em>:\n\nSara Pellegrino, IRC\n\nSenior Vice President, Investor Relations & Corporate Communications\n\n650-260-7120 ext. 264\n\[email protected]\n\nJen Saunders\n\nDirector, Investor Relations & Public Relations\n\n267-485-3119\n\[email protected]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Iovance</em> <em>Biotherapeutics</em> Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - <em>Iovance</em> <em>Biotherapeutics</em> (<em>NASDAQ:IOVA</em>)",
"sentiment": 0.2263,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "3fd5b25b-8fca-4389-b7d6-df94a86c896b",
"title": "ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice - ASLAN Pharma (NASDAQ:ASLN)",
"description": "SAN MATEO, Calif. and SINGAPORE, April 19, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the",
"keywords": "",
"snippet": "Loading... Loading...\n\nSAN MATEO, Calif. and SINGAPORE, April 19, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals ASLN, a clinical-stage, immunology-focused biop...",
"url": "https://www.benzinga.com/pressreleases/24/04/g38343716/aslan-pharmaceuticals-announces-receipt-of-nasdaq-notice",
"image_url": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
"language": "en",
"published_at": "2024-04-19T21:10:00.000000Z",
"source": "benzinga.com",
"relevance_score": null,
"entities": [
{
"symbol": "ASLN",
"name": "ASLAN Pharmaceuticals Limited",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 151.71835,
"sentiment_score": 0.2202,
"highlights": [
{
"highlight": "SAN MATEO, Calif. and SINGAPORE, April 19, 2024 (GLOBE NEWSWIRE) -- <em>ASLAN</em> <em>Pharmaceuticals</em> ASLN, a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it received a letter (the \"Letter\") on April 18, 2024 from The Nasdaq Stock Market (\"Nasdaq\") informing",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>ASLAN</em> <em>Pharmaceuticals</em>\n\n<em>ASLAN</em> <em>Pharmaceuticals</em> ASLN is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients.",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "These statements are based on the current beliefs and expectations of the management of <em>ASLAN</em> <em>Pharmaceuticals</em> <em>Limited</em> and/or its affiliates (the \"Company\").",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>ASLAN</em> <em>Pharmaceuticals</em> Announces Receipt of Nasdaq Notice - ASLAN Pharma (<em>NASDAQ:ASLN</em>)",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "40b79ad3-e55f-4e59-b93f-3325f8d2b472",
"title": "Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive Value (NASDAQ:OCGN)",
"description": "Ocugen is gearing up to report results from the two phase 1/2 studies for the treatment of patients with GA and Stargardt Disease. Check out why OCGN stock is a buy.",
"keywords": "",
"snippet": "Kanizphoto/iStock via Getty Images\n\nOcugen, Inc. (NASDAQ:OCGN) has two upcoming data readouts expected in 2024, both of which could drive shareholder value high...",
"url": "https://seekingalpha.com/article/4684807-ocugen-two-gene-therapy-data-readouts-in-2024-to-drive-value",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1922115254/image_1922115254.jpg?io=getty-c-w1536",
"language": "en",
"published_at": "2024-04-19T21:05:07.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "OCGN",
"name": "Ocugen, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 92.38785,
"sentiment_score": 0.414873,
"highlights": [
{
"highlight": "Kanizphoto/iStock via Getty Images\n\n<em>Ocugen</em>, <em>Inc</em>. (<em>NASDAQ:OCGN</em>) has two upcoming data readouts expected in 2024, both of which could drive shareholder value higher.",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "With two data readouts expected during this year for near-term catalysts, plus a late-stage program for treatment of RP already underway, I believe that <em>Ocugen</em>, <em>Inc</em>. investors could benefit with any potential gains made.",
"sentiment": 0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "OCU-410 and OCU-410ST Readouts As Near-Term Catalysts Could Drive Shareholder Value Higher\n\nAs I noted above, <em>Ocugen</em> is in the process of testing the use of OCU-410 and OCU-410ST as gene therapies for the treatment of patients with Geographic Atrophy [GA] and Stargardt disease.",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "This is a huge market opportunity, and the hope is that <em>Ocugen</em> can get its gene therapy eventually approved to treat this patient population.\n\nWhy is OCU410 an important form of treatment to be advanced? That's because the AAV RORA vector it uses can target the 4 pathways responsible for causing this GA disease.",
"sentiment": 0.9485,
"highlighted_in": "main_text"
},
{
"highlight": "This particular program has a catalyst opportunity, in that <em>Ocugen</em> expects to release preliminary/safety efficacy data from the phase 1/2 ArMaDa study in 2024. This marks the first catalyst opportunity for investors to look forward to this year.",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "Financials\n\nAccording to the 10-K SEC Filing, <em>Ocugen</em> had cash, cash equivalents and investments of $39.5 million as of December 31, 2023. It believed that this would be enough cash to fund its operations into Q4 of 2024.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "With these newly added funds, <em>Ocugen</em>, <em>Inc</em>.'s cash runway should be extended into late 2025. Its cash burn is roughly $75.1 million per year. I believe that it will definitely have to utilize the selling of shares from its S-3 it filed in the coming months.",
"sentiment": 0.5994,
"highlighted_in": "main_text"
},
{
"highlight": "Risks To Business\n\nThere are several risks that investors should be aware of before investing in <em>Ocugen</em>. The first risk to consider would be with the advancement of OCU-410 for the treatment of patients with GA, which is being explored in the ongoing phase 1/2 ArMaDa trial.",
"sentiment": -0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "Conclusion\n\n<em>Ocugen</em>, <em>Inc</em>. is gearing up to report results from the two phase 1/2 studies described above, which are OCU-410 and OCU-410ST for the treatment of patients with GA and Stargardt Disease. I believe that if preliminary safety/efficacy data from both of these studies are positive, then it will significantly boost shareholder value.",
"sentiment": 0.8271,
"highlighted_in": "main_text"
},
{
"highlight": "If <em>Ocugen</em> can eventually receive approval of OCU-400 for this patient population, then its gene therapy will be gene-agnostic. In essence, meaning, the first gene therapy of its kind that can target a broad RP patient population.",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Ocugen</em>: Two Gene Therapy Data Readouts In 2024 To Drive Value (<em>NASDAQ:OCGN</em>)",
"sentiment": 0.34,
"highlighted_in": "title"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "NASDAQ",
"total_documents": 1463,
"sentiment_avg": 0.2602102890018644
}
]
}
Other details
Country
- us
- 5,275